PBYI Puma Biotechnology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PBYI

Price (delayed)

$9.28

Market cap

$479.03M

P/E Ratio

17.19

Dividend/share

N/A

EPS

$0.54

Enterprise value

$447.31M

?
Relative Growth: Rel. Growth: 24
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 65
Relative Profitability: Rel. Profitability: 77

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights ...

Highlights
Puma Biotechnology's debt has shrunk by 90% YoY and by 70% QoQ
Puma Biotechnology's quick ratio has soared by 64% YoY and by 18% from the previous quarter
The net income has contracted by 45% YoY but it has grown by 10% from the previous quarter
PBYI's EPS is down by 45% year-on-year but it is up by 8% since the previous quarter
The P/E is 64% higher than the last 4 quarters average of 11.1
The revenue has contracted by 2.9% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.pumabiotechnology.com
Peers: ARRY PFE

Key stats

What are the main financial stats of PBYI

PBYI stock price

How has the Puma Biotechnology stock price performed over time
Intraday
-5.5%
1 week
-1.17%
1 month
0.43%
1 year
97.03%
YTD
55.97%
QTD
14.43%

Financial performance

How have Puma Biotechnology's revenue and profit performed over time
Revenue
$231.24M
Gross profit
$173.05M
Operating income
$30.44M
Net income
$26.72M
Gross margin
74.8%
Net margin
11.6%
The net income has contracted by 45% YoY but it has grown by 10% from the previous quarter
Puma Biotechnology's net margin has decreased by 43% YoY but it has increased by 8% QoQ
The operating income has contracted by 34% YoY but it has grown by 3.2% from the previous quarter
The operating margin has contracted by 32% YoY

Price vs fundamentals

How does PBYI's price correlate with its fundamentals

Growth

What is Puma Biotechnology's growth rate over time

Valuation

What is Puma Biotechnology stock price valuation
PBYI P/E details
P/E
17.19
P/B
3.41
P/S
2.04
EV/EBIT
12.9
EV/EBITDA
9.9
EV/Sales
1.93
The P/E is 64% higher than the last 4 quarters average of 11.1
PBYI's EPS is down by 45% year-on-year but it is up by 8% since the previous quarter
PBYI's P/B is 44% higher than its last 4 quarters average of 2.5 but 18% lower than its 5-year quarterly average of 4.4
Puma Biotechnology's equity has increased by 32% YoY and by 8% QoQ
PBYI's P/S is 140% above its 5-year quarterly average of 0.9 and 54% above its last 4 quarters average of 1.4
The revenue has contracted by 2.9% YoY

Efficiency

How efficient is Puma Biotechnology business performance
Puma Biotechnology's ROE has plunged by 61% YoY but it has increased by 2.5% from the previous quarter
The ROA has decreased by 43% YoY but it has increased by 10% QoQ
PBYI's ROIC is down by 40% YoY and by 2.9% QoQ
PBYI's return on sales is down by 31% year-on-year

Dividends

What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PBYI.

Financial health

How did Puma Biotechnology financials performed over time
The company's current ratio has surged by 68% YoY and by 22% QoQ
Puma Biotechnology's quick ratio has soared by 64% YoY and by 18% from the previous quarter
Puma Biotechnology's debt is 97% lower than its equity
Puma Biotechnology's debt to equity has shrunk by 94% YoY and by 75% QoQ
Puma Biotechnology's debt has shrunk by 90% YoY and by 70% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.